07:00 , May 10, 2010 |  BC Week In Review  |  Company News

Althea, Altus deal

Althea acquired Altus' assets and IP for an undisclosed sum. The deal includes Altus' cross linked enzyme crystal (CLEC) protein technology and a portfolio of controlled-release injectables, including ALTU-238 . The seven-day recombinant growth hormone...
07:00 , May 10, 2010 |  BioCentury  |  Finance

Picking through the remains

Althea Technologies Inc. acquired the remains of its now defunct manufacturing client Altus Pharmaceuticals Inc. for an undisclosed amount last week, and hopes to create value with the formulation assets while off-loading the early product...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

Altus endocrine news

Altus filed for Chapter 7 bankruptcy. In September, the biotech said it will wind down its business operations and terminate substantially all of its employees. Altus' ALTU-238 , a long-acting subcutaneous formulation of recombinant human...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Company News

Altus endocrine news

Altus said it will wind down its business operations and terminate substantially all of its employees. Altus also suspended its pediatric Phase II trial of ALTU-238 for growth hormone deficiency (GHD). In January, Altus restructured...
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

ALTU-238: Phase II started

Altus disclosed that in March it began an open-label, active-controlled, U.S. Phase II trial (0001194) to compare 0.3, 0.6 or 0.9 mg/kg of subcutaneous ALTU-238 given weekly vs. 0.043 mg/kg Nutropin AQ somatropin given daily...
07:00 , Apr 6, 2009 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Company News

Altus gastrointestinal, endocrine news

Altus will restructure and reduce headcount by 100 (75%) to about 35 to focus on ALTU-238 to treat growth hormone deficiency (GHD). The subcutaneous long-acting formulation of somatropin recombinant human growth hormone (rhGH) has completed...
08:00 , Feb 2, 2009 |  BioCentury  |  Finance

Ebb & Flow

Two separate takeouts involving...
02:19 , Jan 27, 2009 |  BC Extra  |  Company News

Altus drops Trizytek, restructures

Altus (NASDAQ:ALTU) said its limited cash resources allow support of a single clinical development program and thus will discontinue development of its lead compound, Trizytek , to focus on ALTU-238. The company also will reduce...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Clinical News

ALTU-238: Phase Ic data

Data from 36 healthy volunteers in a dose-escalating, U.S. Phase Ic trial showed that Altus' scaled-up ALTU-238 had similar safety, pharmacokinetic and pharmacodynamic profiles to the compound used in prior Phase I and II trials...